Corpay Cross-Border Launches Payments GPS for Live Payment Tracking
Corpay1, a FLEETCOR® (NYSE: FLT) brand and global leader in business payments, is proud to announce that Corpay’s Cross-Border business has launched Payments GPS, a proprietary tracking technology that allows clients and partners to monitor payments in real time.
Leveraging best-in-class technologies, including SWIFT GPI (Global Payments Innovation), Payments GPS allows for a comprehensive infrastructure for clients and partners to continuously monitor payments. It provides an intuitive user experience, API Suite, and push notifications – making payment tracking more convenient than ever before.
“We have witnessed a high demand for transparency in the cross-border payments space. Our vision for Payments GPS is to provide clients and partners with one interface where they can track all payments across Corpay’s networks,” says Corinne MacMillan, Chief Product Officer, Corpay’s Cross-Border Solutions. “And we don’t plan on stopping here. We’re on a mission to continue improving our infrastructure and data-sharing across all networks so we can continue delivering leading-edge transparency.”
Prior to the launch of Payments GPS, understanding the status of payments would require senders to call in or request a payment investigation offline – a process that could take days. Payments GPS drastically reduces these manual touchpoints by providing full details on the payment status, associated fees and any necessary documents clients may need to upload on a centralized platform. Each payment can be easily monitored and tracked using a Tracker ID that is assigned when it is processed by Corpay.
Core benefits of the product include:
- Transparency: Provides real-time payment status from initiation to settlement and allows clients to monitor each step of the journey.
- Centralized platform: Clients can access secure, thorough, and reliable information about the movement of payments across banks, including BIC codes, payment received and released dates, deductions, FX rates, and credited amounts.
- Knowledge: Provides detailed insight into bank fees and other charges upfront, enabling clients to make more informed decisions.
- Certainty: Real-time tracking ensures up-to-date information and gives clients confidence that the payment was successfully delivered to the recipient.
- Convenience: Enables a superior self-serve option for clients and partners, which allows for better exception handling and reduces investigation time and cost.
Providing a transparent self-serve platform for clients will also tremendously reduce the number of payment investigation cases opened for Corpay’s internal operations team.
“In today’s world, transparency is everything. At Corpay, we want our clients to have the same level of visibility and knowledge about the status of their payments as we do,” said Mark Frey, President, Corpay’s Cross-Border Solutions. “Payments GPS marks the first step in our endeavors to build comprehensive infrastructure aimed at increasing transparency throughout the payment process."
For information about Payment GPS and the benefits it can provide, please visit https://cross-border.corpay.com/payment-gps/.
About Corpay
Corpay is a global leader in business payments, helping companies of all sizes better track, manage and pay their expenses. Corpay provides customers with a comprehensive suite of online payment solutions including Bill Payment, AP Automation, Cross-Border Payments, Currency Risk Management, and Commercial Card Programs. Corpay is part of the FLEETCOR (NYSE: FLT) portfolio of brands. To learn more, visit www.corpay.com.
1“Corpay” (a Fleetcor (NYSE: FLT) brand) in this document primarily refers to the Cross-Border Division of Corpay https://www.corpay.com/cross-border; a full listing of the companies that are part of the Corpay brand is available here: https://www.corpay.com/compliance.
* Subject to credit and compliance approval from the relevant Corpay company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912182602/en/
Contact information
Media:
Keera Hart
Senior Account Director
(905) 580-1257
Keera.Hart@kaiserpartners.com
Corpay:
Brad Loder
VP, Cross-Border Marketing
(647) 627-6635
brad.loder@corpay.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 10:00:00 EET | Press release
With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global international showcase for food innovation, allowing brands and companies to ex
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom